Koas acquires antibody drug developer Novelty Nobility

CAR-T Digest - August 2020

23 August 2025: Koas acquires antibody drug developer Novelty Nobility

Koas, Korea’s top office furniture maker, announced a KRW 50 billion investment to acquire Novelty Nobility, making it a subsidiary and marking its full-scale entry into the pharmaceutical and biotechnology industry
Novelty Nobility specializes in antibody-based drug development, with pipelines targeting autoimmune diseases and next-generation ADCs, and is recognized for its innovative antibody platform technology
Its ADC pipeline includes NN3201 and NN3206, both featuring novel payloads; NN3206 was selected for Johnson & Johnson’s JLAB incubator, while NN3201 has drawn attention from global pharma players with checkpoint inhibitor portfolios
With this acquisition, Koas secures a strategic foothold in ADC innovation, planning global partnerships and a large-scale technology licensing deal by 2026